Abiopharma

Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025

Mesoblast Participation at Piper Sandler Conference

Acadia Healthcare Company, Inc. (ACHC) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Mesa Laboratories, Inc. to Announce Third Quarter Results on February 3, 2026

The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

Aurigene Oncology anuncia los prometedores resultados iniciales de los dos primeros cohortes del estudio de fase 1 de AUR112, un inhibidor oral de MALT1 de molécula pequeña, en neoplasias linfoides recidivadas o refractarias

Aurigene Oncology Limited maakt bemoedigende eerste resultaten bekend van eerste twee cohorten van fase 1-onderzoek naar AUR112, een orale remmer van MALT1, bij recidiverende/refractaire lymfoïde maligniteiten

Announcement relating to despatch of Definitive Proxy Statement and details of Scheme Meeting and Extraordinary General Meeting

Aurigene Oncology Limited annuncia dati iniziali incoraggianti dalle prime due coorti dello studio di Fase 1 di AUR112, un inibitore orale a piccola molecola di MALT1, nei linfomi recidivanti/refrattari

Aurigene Oncology Limited gibt vielversprechende erste Daten aus den ersten beiden Kohorten der Phase-1-Studie zu AUR112 bekannt, einem oral verabreichten niedermolekularen Inhibitor von MALT1, bei wieder auftretenden oder hartnäckigen...